Moderna MRNA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$3.19B+4.9% | -$2.82B+20.8% | -$3.12B-27.7% | -$2.9B+52.3% | -$3.36B+45.7% | ||
| $235M+22.4% | $215M+13.8% | $208M-37.2% | $208M-60.6% | $192M-66.8% | ||
| $472M+6.5% | $483M+12.6% | $474M+17.3% | $461M+24.9% | $443M+33.8% | ||
| $10M+112% | -$156M+72.1% | -$503M-53.4% | -$115M-21.1% | -$85M+91.3% | ||
| —— | —— | -$78M-1.3% | -$158M+50.0% | -$168M+61.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$161M+14.4% | -$153M-5.5% | -$208M+76.4% | $8M+100% | -$188M+90.7% | ||
| —— | —— | $4M0.0% | $120M+208% | -$8M-104% | ||
| -$81M-35.0% | -$77M-26.2% | -$104M— | -$90M— | -$60M— | ||
| —— | —— | -$154M+85.5% | -$517M+44.7% | -$435M+65.9% | ||
| -$23M— | -$21M— | —— | —— | —— | ||
| —— | —— | —— | —— | -$47M-56.7% | ||
| —— | —— | —— | —— | —— | ||
| $137M-85.9% | $192M-81.7% | $675M-9.9% | $793M+7.5% | $972M+23.0% | ||
| $5.35B-6.9% | $5.77B-11.7% | $6.11B-3.1% | $6.2B+5.6% | $5.75B+10.2% | ||
| $2.27B-32.7% | $2.35B-40.7% | $2.7B-22.6% | $3.03B+9.0% | $3.37B+33.0% | ||
| —— | —— | —— | —— | $10M— | ||
| $1.19B— | $1.99B— | —— | —— | —— | ||
| —— | $600M— | $450M— | $300M— | $150M— | ||
| $51M-5.6% | $35M-47.0% | $30M-57.1% | $36M-47.1% | $54M+3.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $22M— | $16.5M— | $11M— | $5.5M— | ||
| $607M+1,139% | $594M+907% | $13M+126% | $24M+120% | $49M+106% | ||
| $3M— | $2M— | $1M— | $1M— | —— | ||
| $283M— | $668M— | —— | —— | —— | ||
| —— | $10M-58.3% | $13.5M-51.4% | $17M-46.0% | $20.5M-41.8% | ||
| —— | $26M-86.8% | $68.75M+17.5% | $111.5M+239% | $154.25M+171% | ||
| —— | —— | —— | —— | -$47M-56.7% | ||
| -$23M— | -$21M— | —— | —— | —— | ||
| -$161M+14.4% | -$153M-5.5% | -$208M+76.4% | $8M+100% | -$188M+90.7% | ||
| -$40M— | -$38M— | —— | —— | —— | ||
| $59M-32.2% | $67M-29.5% | $73M-24.0% | $77M-11.5% | $87M+22.5% | ||
| $235M+22.4% | $215M+13.8% | $208M-37.2% | $208M-60.6% | $192M-66.8% | ||
| -$81M-35.0% | -$77M-26.2% | -$104M— | -$90M— | -$60M— | ||
| —— | —— | —— | —— | $10M— | ||
| $4.36B-26.3% | $5.56B0.0% | $5.55B+0.7% | $5.45B-6.8% | $5.92B+2.3% | ||
| $2.27B-32.7% | $2.35B-40.7% | $2.7B-22.6% | $3.03B+9.0% | $3.37B+33.0% | ||
| $20M+186% | $18M+80.0% | $20M-83.3% | $14M-92.6% | $7M-97.2% | ||
| —— | $22M— | $16.5M— | $11M— | $5.5M— | ||
| $51M-5.6% | $35M-47.0% | $30M-57.1% | $36M-47.1% | $54M+3.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $26M-86.8% | $68.75M+17.5% | $111.5M+239% | $154.25M+171% | ||
| —— | —— | -$2.96B— | -$3.79B— | -$4.33B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Moderna generate?
- Moderna (MRNA) generated -$3.4B in operating cash flow over the trailing twelve months.
- What is Moderna's free cash flow?
- After $137.0M of capital expenditures, Moderna's free cash flow was -$3.6B over the trailing twelve months, up 16.3% year over year.
- Where does Moderna's cash flow data come from?
- Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
